Red Light Treatment in Peripheral Artery Disease
Primary Purpose
Peripheral Artery Disease, Claudication, Intermittent, Vasodilation
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Red Light (670 nm energy)
Octafluoropropane
Sponsored by
About this trial
This is an interventional basic science trial for Peripheral Artery Disease focused on measuring red light, vasodilation, nitric oxide
Eligibility Criteria
Inclusion Criteria:
- Participants will be subjects between the ages of 18 and 85 who have been diagnosed with peripheral artery disease. Men and women will be recruited for participation. All ethnicities will be included in this study.
Diagnosis of peripheral artery disease is defined as an Ankle Brachial index of <0.9 or greater than 1.1 either at rest or during treadmill exercise.
Exclusion Criteria:
- Exclusionary criteria include age under 18 years and over 85 years, those who are unable to understand the consent process , those who cannot read or speak English, active pregnancy, hypersensitivity to perflutren contrast agents, pulmonary hypertension, active illicit drug use, untreated blood pressure over 160/95, sickle cell disease, or a history of intracardiac shunt. Additional exclusion criteria neurological diseases such as spinal stenosis, unspecified pain disorders, and any uncontrolled medical conditions.
Sites / Locations
- Medical College of WisconsinRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Red Light treatment
Arm Description
This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
Outcomes
Primary Outcome Measures
Changes in blood flow
Video intensity units from contrast images will be converted to ml/min/g tissue
Secondary Outcome Measures
Changes in nitric oxide metabolites
NO measurement by ozone chemiluminescence
Full Information
NCT ID
NCT03203239
First Posted
June 27, 2017
Last Updated
August 22, 2023
Sponsor
Medical College of Wisconsin
1. Study Identification
Unique Protocol Identification Number
NCT03203239
Brief Title
Red Light Treatment in Peripheral Artery Disease
Official Title
Vasodilatory Effects of Light on Peripheral Artery Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 17, 2018 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical College of Wisconsin
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (<.9 or >1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.
Detailed Description
The intent of this protocol is to measure blood flow in the gastrocnemius muscle in patients with documented peripheral artery disease before and after exposure to 670 nm light energy. The study consists of one visit. Blood flow measurement will be performed using contrast enhanced ultrasound, a method by which ultrasound contrast is continuously infused into the blood stream. Ultrasound records images in the area of interest and flow is related to the intensity of the contrast in each image. Blood will be drawn to measure nitric oxide metabolites. The study is designed to consist of one visit. However, if the protocol changes or the data quality initially collected is uninterpretable, subjects may be asked to return to allow for a standard methodology across all participants. In this case, the subjects who are asked to return will be subject to the same informed consent process a second time. The two visits will be at least one week apart to further reduce the already minimal risks of the study. This will also limit the number of study participants required to gather the necessary data to complete the study, thereby limiting the risks of the study to a smaller number of participants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease, Claudication, Intermittent, Vasodilation
Keywords
red light, vasodilation, nitric oxide
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a single group study in which the subject undergoes a single exposure to red light.
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Red Light treatment
Arm Type
Experimental
Arm Description
This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
Intervention Type
Device
Intervention Name(s)
Red Light (670 nm energy)
Intervention Description
Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
Intervention Type
Drug
Intervention Name(s)
Octafluoropropane
Other Intervention Name(s)
Definity
Intervention Description
All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
Primary Outcome Measure Information:
Title
Changes in blood flow
Description
Video intensity units from contrast images will be converted to ml/min/g tissue
Time Frame
Baseline, 5 min of light, and up to 1 min after discontinuation of light
Secondary Outcome Measure Information:
Title
Changes in nitric oxide metabolites
Description
NO measurement by ozone chemiluminescence
Time Frame
Baseline and 1 min after discontinuation of light
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants will be subjects between the ages of 18 and 85 who have been diagnosed with peripheral artery disease. Men and women will be recruited for participation. All ethnicities will be included in this study.
Diagnosis of peripheral artery disease is defined as an Ankle Brachial index of <0.9 or greater than 1.1 either at rest or during treadmill exercise.
Exclusion Criteria:
Exclusionary criteria include age under 18 years and over 85 years, those who are unable to understand the consent process , those who cannot read or speak English, active pregnancy, hypersensitivity to perflutren contrast agents, pulmonary hypertension, active illicit drug use, untreated blood pressure over 160/95, sickle cell disease, or a history of intracardiac shunt. Additional exclusion criteria neurological diseases such as spinal stenosis, unspecified pain disorders, and any uncontrolled medical conditions.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicole L Lohr, MD,PHD
Phone
414-996-3504
Email
nlohr@uabmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicole L Lohr, MD,PHD
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole L Lohr, MD PhD
Phone
205-996-3504
Email
nlohr@uabmc.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Red Light Treatment in Peripheral Artery Disease
We'll reach out to this number within 24 hrs